纤溶酶对进展型脑梗死高敏C反应蛋白的影响

Effect of Fibrinolysin on High-sensitivity C-reactive Protein of Progressive Cerebral Infarction

【目的】研究纤溶酶对进展型脑梗死患者血清高敏C反应蛋白（hs_CRP）的影响。【方法】入住本院129例进展型脑梗死患者分为观察组（67例）与对照组（62例）。对照组按神经内科常规治疗，治疗组在对照组治疗基础上加用纤溶酶100mg／d。治疗7d、14d，观察两组疗效及患者血清hs—CRP水平的变化。【结果】观察组治疗后总有效率（82．1％），显著高于对照组的总有效率（58．1％）（P〈0．05）；观察组血清hs—CRP的水平治疗后7d、14d与治疗前比较显著降低（P〈0．05或尸〈0．01），且显著低于同期对照纽（P〈0．05）。【结论】纤溶酶能显著降低进展型脑梗死患者hs—CRP水平，提高临床疗效。

[Objective] To investigate the effect of fibrinolysin on serum high-sensitivity C-reactive protein （hs- CRP） in patients with progressive cerebral infarction. [Methods] A total of 129 patients with progressive cerebral infarction admitted in our hospital were divided into observation group（n=67） and control group（n= 62）. The control group received routine treatment in neurological department, while the observation group re- ceived fibrinolysin 100 mg/d on the basis of the treatment of the control group. The efficacy and serum hs-CRP in two groups 7d and 14d after treatment were observed. [Results] After treatment, the total effective rate in observation group was 82. 1%, which was significantly higher than that in control group （58. 1 %） （ P G 0.05）. Compared with before treatment, serum hs-CRP in observation group 7d and 14d after treatment was decreased significantly（ P 〈0.05 or P 〈0.01）, and significantly lower than that in concurrent control group （ P 〈0.05）. [Conclusion] Fibrinolysin can significantly reduce hs- CRP level in patients with progressive cer- ebral infarction and improve clinical outcomes.